The landscape of CAR T-cell therapy for relapsed/refractory large B-cell lymphoma (LBCL) is changing, particularly in light of recent findings from the UK. This study, involving nine centers, explored the implications of out-of-specification (OOS) CAR T-cell products for patients who have exhausted other treatment options.
Understanding CAR T Manufacturing Failures
CAR T-cell therapy involves genetically modifying a patient’s T-cells to better target cancer cells. However, manufacturing failures are a significant hurdle, particularly for patients with non-Hodgkin lymphoma, where the failure rate can reach approximately 25%. This is notably higher than the 1% to 13% manufacturing failure rates observed in other patient populations eligible for CAR T therapy.
In this study, researchers assessed the outcomes of patients who received either axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel). The data, collected from January 2019 to January 2023, encompassed 805 patients approved by the UK National CAR T Clinical panel.
Efficacy of OOS Products
Despite the manufacturing failures, OOS CAR T-cell therapy showed promise. About 50% of remanufactured products successfully met specifications, indicating that OOS products might still provide a therapeutic option when standard treatments are unavailable.
Among the patients studied, 3.9% encountered at least one manufacturing failure: 3.5% for axi-cel and 5.7% for tisa-cel. A total of 38 patients were affected, with 18 experiencing OOS products. Notably, most of these patients were male with de novo diffuse LBCL and had undergone multiple treatment lines prior to CAR T-cell therapy.
Factors Contributing to Manufacturing Failure
The study revealed that the reasons for manufacturing failures were consistent over time, with low cell viability and T-cell purity being the primary culprits. In addition, prior treatments, particularly bendamustine, emerged as a significant risk factor for manufacturing failure. Specifically, nearly 29% of manufacturing failures were linked to patients who had received bendamustine within six months of apheresis.
Comparative Outcomes of Infusions
When comparing the outcomes of patients who received OOS infusions to those who received in-specification products, the results were encouraging. No significant differences were found in overall response rates or survival at one or three months post-infusion.
Cytokine release syndrome (CRS), a common side effect of CAR T therapy, was observed in 83.3% of the OOS group, while the control group showed a slightly higher incidence. These findings suggest that patients receiving OOS infusions may not face increased risks compared to those receiving standard products.
Investigating Long-Term Outcomes
The long-term outcomes of patients infused with OOS products were consistent with those of the control group. Overall survival rates after one year showed no significant difference, indicating that OOS products may be a viable option when standard therapies fail.
However, the study did note four patient deaths, with one from the OOS group due to unknown causes. The other three deaths were linked to infections and were within the control group.
Limitations and Future Directions
The findings of this study do come with limitations. The patient cohort consisted of individuals approved for advanced CAR T therapy, which could skew the risk assessments for manufacturing failure. Additionally, the small sample size may limit the generalizability of the results.
Future research will need to explore the effects of the manufacturing process in greater detail and examine the implications of treatment variabilities.
Conclusion
The study highlights the potential of OOS CAR T products as a treatment avenue for patients with LBCL facing limited options. With a significant percentage of remanufactured products meeting specifications and comparable outcomes to standard treatments, there is reason for optimism. As the field of CAR T therapy continues to evolve, further investigations will be essential to refine manufacturing processes and enhance patient outcomes.
Key Takeaways:
- The manufacturing failure rate for CAR T therapy in LBCL patients is approximately 25%, significantly higher than other cancer types.
- OOS CAR T products demonstrated successful remanufacturing in about 50% of cases, offering potential treatment options for patients.
-
No significant differences in overall response or survival rates were observed between OOS and standard CAR T infusions.
-
Bendamustine treatment within six months prior to apheresis was identified as a risk factor for manufacturing failures.
-
Future studies should address the variables affecting manufacturing processes and evaluate broader patient cohorts.
Read more → www.ajmc.com